Autifony Therapeutics Ltd

Autifony Therapeutics is developing pharmaceutical treatments for hearing disorders, which affect a significant proportion of the population. Autifony‘s approach is focused on Kv3 potassium channel modulation, a novel mechanism of action. These ion channels regulate neuronal activity within the auditory system, and our new drugs aim to treat age related hearing loss and tinnitus. The lead programme has completed Phase I clinical trials and is about to start two Phase IIa studies – for age related hearing loss in the US, and for tinnitus in the UK (supported by funding from the Technology Strategy Board).

Given Autifony’s focus on modulation of Kv3 channels, which have also been implicated in other neurological and psychiatric disorders, there are opportunities for Autifony to investigate these other indications with compounds with different profiles. Autifony was awarded Technology Strategy Board funding to progress the development of a candidate drug for the treatment of schizophrenia, working together with academic collaborators at the Universities of Manchester and Newcastle.

Autifony Therapeutics Limited was formed in 2011 as a spin-out from GSK. The company is privately funded by leading venture capital investors SV Life Sciences, Imperial Innovations and Pfizer Venture Investments. Autifony’s head office is at the Imperial College Incubator in London, and has a subsidiary with medicinal chemistry and biology labs based in Verona, Italy.

Website:
www.autifony.com
Membership affiliation
Keywords
hearing, tinnitus, schizophrenia, CNS, drug discovery, drug development
Organisation type
Dr Barbara Domayne-Hayman
Chief Business Officer 

Cambridge Bioscience

Cambridge Bioscience is a well established, leading European distributor of life science products bringing new and exciting technologies to researchers. Working with over forty specialist suppliers around the world, we offer an innovative, extensive and diverse range of over 450,000 products, services and instruments supporting research in the areas of drug discovery, regenerative medicine, cell culture and much more.

The products and services Cambridge Bioscience offers includes:
·         Ion Channel, GPCR & Kinase Profiling Services
·         Primary screening  & Secondary Drug Profiling Services
·         Cardiac Safety Assessment
·         Ion Channel & GPCR Cell Lines
·         Human Tissues, TMAs & Biofluids
·         Primary Cells & Cell Culture Technologies

To find out more, please meet us at the event or contact us using the details below
Cambridge Bioscience
Munro House
Trafalgar Way
Bar Hill
Cambridge 
United Kingdom
CB23 8SQ

Tel: +44 (0)1223 316 855
Fax: +44 (0)1954 781 323
Email: support@bioscience.co.uk
Website: www.bioscience.co.uk

Organisation type
Keywords
distributor
Membership affiliation
Dr Vashu Pamnani
Senior Business Manager 

Clinical Network Services (UK) Ltd

Clinical Network Services (CNS) is an Australian, New Zealand and UK based service group, offering full and integrated drug development consultancy to small – medium sized Biotech companies from inception through to end of phase II clinical trial programs. CNS offers a unique service that brings together BioDesk; an intelligent product development and regulatory planning service, with our highly experienced regional clinical operations and data management teams.

BioDesk is a team of in-house scientists and commercial drug development experts, who work closely with our clients from the earliest of planning stages. Together they create and manage Drug Development Plans, including all stages of pre-clinical/CMC programs that embrace global regulatory strategies whilst leveraging our unique regional advantage.

Australia and New Zealand have an outstanding product development timeline advantage due to our access to a pragmatic regulatory environment that makes it possible to add value to the global regulatory dossier and enter the clinic quickly, without the need for prior approval from another regulatory agency. Our clients have often established initial proof-of-concept quickly, and have enjoyed a time(cost) saving when compared to the more resource-intensive strategy of applying for an IND or CTA.

CNS has worked with clients whose cumulative acquisition price exceeds US$16.5billion; many of these clients initially fast-tracked their programs by running their phase 1 & 2 studies in Australia and New Zealand.

Further information on CNS can be found at www.clinical.net.au

Organisation type
Keywords
product development,regulatory,consultancy
Membership affiliation
Mr Paul Cronin
Director, Business Development 
Mr Russell Neal
Director 

One Nucleus

About One Nucleus

Established in May 2010, One Nucleus is the result of the merger of ERBI and London Biotechnology Network. One Nucleus is a not-for-profit membership organisation for international life science and healthcare companies and the largest of its kind in Europe. The company is based in Cambridge UK and London, at the heart of Europe's largest cluster. The 470 members include pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial Service Providers.

Organisation type
Keywords
Life science, membership, commercial, Service, Providers
Membership affiliation
Mr Tony Jones
Director, Business Development 

Selcia Limited

Selcia Limited is leading provider of contract research services in drug discovery and 14C radiolabelling, with a GLP analytical laboratory, in Ongar, Essex, UK.

Website:
www.selcia.com
Organisation type
Keywords
CRO
Membership affiliation
Mr Dave Roberts
BD Director Radiochemistry